Trial to Test Malarial Drug in Breast Cancer Treatment
Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive?
That’s what researchers at Mason’s Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to find out.
In January, the IBCI and CAPMM launched the PINC Trial, short for Preventing Invasive Breast Neoplasia with Chloroquine.
This three-year clinical trial will test the effectiveness of the anti-malarial drug chloroquine in treating 90 women with ductal carcinoma in situ (DCIS), a type of breast cancer in which the cancer cells start in the milk ducts but have not yet become invasive and spread in the breast.
To read more, visit http://news.gmu.edu/articles/1943.